RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
New Horizon Health, a Beijing-Hangzhou company developing early-stage cancer screening products, raised $20 million in a B round led by Qiming Venture Partners. New Horizon’s first product is a home-based test for colorectal cancer using fecal gene analysis (FIT-DNA) technology. Horizon believes the test can detect precancerous lesions five years earlier than blood tests. Using a colonoscopy, the lesions can be removed before they become cancerous. Previous investors Legend Capital and SoftBank China also participated in the B round.
Source: ChinaBio Today
